Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1

Journal of Immunology

Volumn 186, Issue 12, 2011, Pages 7127-7135

  Turner Brannen, Emily ^a   Choi, Ka Yee Grace ^a   Arsenault, Ryan ^b   El Gabalawy, Hani ^a   Napper, Scott ^b   Mookherjee, Neeloffer ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 32; PROTEIN P300; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; STIMULATION; SYNOVIOCYTE; TRANSCRIPTION INITIATION;

APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; INTERLEUKINS; P300-CBP TRANSCRIPTION FACTORS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 79959553437     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002306     Document Type: Article

References (41)

1. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
2. Martel-Pelletier, J., D. J. Welsch, and J. P. Pelletier. 2001. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 15: 805-829.
3. Padyukov, L., J. Lampa, M. Heimbürger, S. Ernestam, T. Cederholm, I. Lundkvist, P. Andersson, Y. Hermansson, A. Harju, L. Klareskog, and J. Bratt. 2003. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62: 526-529.
4. van den Berg, W. B. 2000. Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. 59(Suppl 1): i81-i84.
5. Huber, L. C., O. Distler, I. Tarner, R. E. Gay, S. Gay, and T. Pap. 2006. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 45: 669-675. (Pubitemid 43985334)
6. Choy, E. H., and G. S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344: 907-916.
7. Gaffen, S. L. 2004. Biology of recently discovered cytokines: interleukin-17 - a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res. Ther. 6: 240-247.
8. Dinarello, C. A., and S. H. Kim. 2006. IL-32, a novel cytokine with a possible role in disease. Ann. Rheum. Dis. 65(Suppl 3): iii61-iii64.
9. Joosten, L. A., M. G. Netea, S. H. Kim, D. Y. Yoon, B. Oppers-Walgreen, T. R. Radstake, P. Barrera, F. A. van de Loo, C. A. Dinarello, and W. B. van den Berg. 2006. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 103: 3298-3303.
10. Calabrese, F., S. Baraldo, E. Bazzan, F. Lunardi, F. Rea, P. Maestrelli, G. Turato, K. Lokar-Oliani, A. Papi, R. Zuin, et al. 2008. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178: 894-901.
11. Meyer, N., M. Zimmermann, S. Burgler, C. Bassin, S. Woehrl, K. Moritz, C. Rhyner, P. Indermitte, P. Schmid-Grendelmeier, M. Akdis, et al. 2010. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J. Allergy Clin. Immunol. 125: 858-865.e810.
12. Mabilleau, G., and A. Sabokbar. 2009. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE 4: e4173.
13. Koenders, M. I., E. Lubberts, F. A. van de Loo, B. Oppers-Walgreen, L. van den Bersselaar, M. M. Helsen, J. K. Kolls, F. E. Di Padova, L. A. Joosten, and W. B. van den Berg. 2006. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J. Immunol. 176: 6262-6269.
14. Lubberts, E. 2008. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 41: 84-91.
15. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.
16. Koenders, M. I., L. A. Joosten, and W. B. van den Berg. 2006. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann. Rheum. Dis. 65(Suppl 3): iii29-iii33.
17. Shoda, H., K. Fujio, Y. Yamaguchi, A. Okamoto, T. Sawada, Y. Kochi, and K. Yamamoto. 2006. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res. Ther. 8: R166.
18. Mookherjee, N., K. L. Brown, D. M. Bowdish, S. Doria, R. Falsafi, K. Hokamp, F. M. Roche, R. Mu, G. H. Doho, J. Pistolic, et al. 2006. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176: 2455-2464. (Pubitemid 43201696)
19. Jalal, S., R. Arsenault, A. A. Potter, L. A. Babiuk, P. J. Griebel, and S. Napper. 2009. Genome to kinome: species-specific peptide arrays for kinome analysis. Sci. Signal. 2: pl1.
20. Turner, N. A., R. S. Mughal, P. Warburton, D. J. O'Regan, S. G. Ball, and K. E. Porter. 2007. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc. Res. 76: 81-90.
21. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29: e45.
22. Kim, S. H., S. Y. Han, T. Azam, D. Y. Yoon, and C. A. Dinarello. 2005. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22: 131-142.
23. Cohen, P. 2002. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1: 309-315.
24. Sawyers, C. L. 2002. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12: 111-115.
25. Henness, S., E. van Thoor, Q. Ge, C. L. Armour, J. M. Hughes, and A. J. Ammit. 2006. IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L1283-L1290.
26. Hartupee, J., C. Liu, M. Novotny, X. Li, and T. Hamilton. 2007. IL-17 enhances chemokine gene expression through mRNA stabilization. J. Immunol. 179: 4135-4141.
27. Shioya, M., A. Nishida, Y. Yagi, A. Ogawa, T. Tsujikawa, S. Kim-Mitsuyama, A. Takayanagi, N. Shimizu, Y. Fujiyama, and A. Andoh. 2007. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin. Exp. Immunol. 149: 480-486.
28. Huang, F., C. Y. Kao, S. Wachi, P. Thai, J. Ryu, and R. Wu. 2007. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 179: 6504-6513.
29. Iwanami, K., I. Matsumoto, Y. Tanaka-Watanabe, A. Inoue, M. Mihara, Y. Ohsugi, M. Mamura, D. Goto, S. Ito, A. Tsutsumi, et al. 2008. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 58: 754-763. (Pubitemid 351364873)
30. Onishi, R. M., and S. L. Gaffen. 2010. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129: 311-321.
31. de Boer, O. J., J. J. van der Meer, P. Teeling, C. M. van der Loos, M. M. Idu, F. van Maldegem, J. Aten, and A. C. van der Wal. 2010. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J. Pathol. 220: 499-508.
32. Asquith, D. L., and I. B. McInnes. 2007. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251.
33. Novick, D., M. Rubinstein, T. Azam, A. Rabinkov, C. A. Dinarello, and S. H. Kim. 2006. Proteinase 3 is an IL-32 binding protein. Proc. Natl. Acad. Sci. USA 103: 3316-3321.
34. Lee, C. W., I. T. Lee, C. C. Lin, H. C. Lee, W. N. Lin, and C. M. Yang. 2010. Activation and induction of cytosolic phospholipase A2 by IL-1beta in human tracheal smooth muscle cells: role of MAPKs/p300 and NF-kappaB. J. Cell. Biochem. 109: 1045-1056.
35. Huang, W. C., and C. C. Chen. 2005. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol. Cell. Biol. 25: 6592-6602.
36. Ke, Y., G. Jiang, D. Sun, H. J. Kaplan, and H. Shao. 2009. Retinal astrocytes respond to IL-17 differently than retinal pigment epithelial cells. J. Leukoc. Biol. 86: 1377-1384.
37. Kim, D. H., H. H. Nelson, J. K. Wiencke, D. C. Christiani, J. C. Wain, E. J. Mark, and K. T. Kelsey. 2001. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20: 1765-1770.
38. Kuester, D., A. A. Dar, C. C. Moskaluk, S. Krueger, F. Meyer, R. Hartig, M. Stolte, P. Malfertheiner, H. Lippert, A. Roessner, et al. 2007. Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia 9: 236-245. (Pubitemid 46457240)
39. Raval, A., S. M. Tanner, J. C. Byrd, E. B. Angerman, J. D. Perko, S. S. Chen, B. Hackanson, M. R. Grever, D. M. Lucas, J. J. Matkovic, et al. 2007. Down-regulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129: 879-890. (Pubitemid 46813150)
40. Hahn, M. A., T. Hahn, D. H. Lee, R. S. Esworthy, B. W. Kim, A. D. Riggs, F. F. Chu, and G. P. Pfeifer. 2008. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 68: 10280-10289.
41. Cuny, G. D. 2009. Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr. Pharm. Des. 15: 3919-3939.